FLT3 and acute myeloid leukemia: Combination therapies, particularly with hypomethylating agents (HAM) and the combination of cladribine, high-dose cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M), have shown better outcomes in FLT3-mutated AML (22).